psoriasis
Novartis reveals impressive four year data upon Cosentyx
October 3, 2016Sales and Marketing Cosentyx, Novartis, psoriasis
Novartis announced on October 1 that Cosentyx (secukinumab) had delivered a high percentage and long-lasting skin clearance in patients with …
Valeant’s psoriasis drug “difficult to assess”, according to FDA staff
July 18, 2016Research and Development, Sales and Marketing FDA, Valeant, psoriasis
Staff at the US Food and Drug Administration have expressed concerns over Valeant’s psoriasis candidate, brodalumab, due to the potential …
Eli Lilly gets European marketing authorisation for psoriasis drug
April 26, 2016EC, EU, Eli Lilly, drug trial, psoriasis, regulation
US pharma firm Eli Lilly and Co (NYSE: LLY) on Tuesday said the European Commission backed marketing authorisation for its …
Vitae Pharma soars on positive mid-stage trial results for psoriasis drug
March 17, 2016Business Services, Research and Development, Sales and Marketing Vitae Pharmaceuticals, drug trial, psoriasis, research
Shares in Vitae Pharmaceuticals (Nasdaq: VTAE) nearly doubled in pre-market trading Thursday after the company reported mid-stage trials of its psoriasis …
AbbVie pays $595m upfront for experimental Boehringer psoriasis drug
March 8, 2016Manufacturing and Production, Research and Development, Sales and Marketing AbbVie, BI 655066, Boehringer Ingelheim, psoriasis
AbbVie is betting big on the future of an experimental psoriasis drug, paying $595m upfront for the rights to Boehringer …
Eli Lilly’s plaque psoriasis treatment impresses in Phase III trials
March 7, 2016Research and Development, Sales and Marketing Eli Lilly, Enbrel, ixekizumab, psoriasis
Eli Lilly has announced late-stage trial data showing ixekuzimab treatment resulted in clinically meaningful improvements in as early as one …
CHMP recommends Lilly psoriasis drug for approval
February 29, 2016Research and Development Eli Lilly, Taltz, psoriasis
Eli Lilly’s Taltz (ixekizumab) has received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for …
Novartis psoriasis drug shows three-year efficacy
October 12, 2015Cosentyx, EADV, Novartis, Secukinumab, psoriasis
Novartis has announced new trial data confirming the efficacy of Cosentyx in patients with moderate-to-severe plaque psoriasis. The results of …
NICE U-turn on Janssen arthritis drug
June 4, 2015Sales and Marketing Janssen, NICE, Stelara, psoriasis, uturn
NICE has performed a U-turn on Janssen’s Stelara and has now recommended the drug for the treatment of psoriatic arthritis. …
Amgen pulls out of psoriasis deal with AstraZeneca
May 26, 2015Sales and Marketing Amgen, AstraZeneca, psoriasis
Amgen has ended its agreement with AstraZeneca to develop a new biologic for psoriasis, because of the likelihood of ‘restrictive …
Pfizer, Novartis and Celgene among late-stage psoriasis trial advances
March 23, 2015Sales and Marketing Celgene, Cosentyx, Enbrel, FDA, Novartis, Pfizer, otezla, psoriasis, tofacitinib
Pfizer bosses say they are confident of a positive FDA application for tofacitinib after announcing positive Phase III study results. …
AstraZeneca enters autoimmune diseases pact with Orca
February 25, 2015Research and Development, Sales and Marketing AstraZeneca, autoimmune, orca, orphan nuclear receptor gamma inhibitors, psoriasis, retinoic
AstraZeneca has signed a three-year research deal with the UK-based biotech firm Orca to develop treatments for autoimmune diseases. The …
Sanofi enters autoimmune diseases pact with Lead Pharma
February 18, 2015Research and Development, Sales and Marketing Sanofi, autoimmune, biox, lead pharma, psoriasis
Sanofi is to collaborate with Dutch biotech firm Lead Pharma to develop treatments for autoimmune diseases. The companies will work …
Novartis gets FDA approval for psoriasis drug
January 22, 2015Sales and Marketing Cosentyx, European Commission, FDA, Novartis, Secukinumab, psoriasis
The US Food and Drug Administration (FDA) has shown Novartis’ skin condition drug Cosentyx the green light to treat patients …
AbbVie highlights treatment adherence
June 12, 2014Sales and Marketing ALIGN, AbbVie, Abbott, Crohn’s disease, TNF, ankylosing spondylitis, psoriasis, psoriatic arthritis, rheumatoid arthritis, treatment, ulcerative colitis
Patients with inflammatory diseases tend to be better at following their treatment regimes with TNF inhibitors rather than other medicines, …
Latest content
Boyds expands Regulatory Affairs team to support growing demand
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time
Blood sensor detects Parkinson’s-associated proteins in 40 minutes
